## Clinical Diagnosis: Cancer-Associated Disseminated Intravascular Coagulation (DIC) ### Pathophysiology of Cancer-Associated DIC **Key Point:** Malignancies, especially pancreatic and lung cancers, release tissue factor (TF) and cancer procoagulant into the circulation, triggering uncontrolled thrombin generation and consumption of platelets, fibrinogen, and clotting factors. ### Classic DIC Pentad in This Patient 1. **Thrombocytopenia** (45,000/μL) — consumption of platelets 2. **Prolonged PT and aPTT** — consumption of factors II, V, VII, X 3. **Low fibrinogen** (95 mg/dL) — consumption and ongoing thrombin generation 4. **Elevated D-dimer** — massive fibrin formation and degradation 5. **Schistocytes on smear** — mechanical fragmentation of RBCs in fibrin strands ### DIC Scoring and Diagnostic Criteria **High-Yield:** The International Society on Thrombosis and Haemostasis (ISTH) DIC score combines: - Platelet count - D-dimer/FDP elevation - PT prolongation - Fibrinogen level A score ≥5 is compatible with overt DIC. This patient scores ≥6. ### Differential Diagnosis: Why Not the Other Options? | Feature | Cancer DIC | APL-DIC | HIT | APS | | --- | --- | --- | --- | --- | | **Platelets** | ↓↓ (consumption) | ↓↓ (consumption) | ↓ (immune) | Normal or ↑ | | **PT/aPTT** | ↑↑ (consumption) | ↑↑ (consumption) | Normal | Normal or ↑ | | **Fibrinogen** | ↓↓ (consumption) | ↓↓ (consumption) | Normal | Normal | | **D-dimer** | ↑↑↑ (marked) | ↑↑↑ (marked) | Normal | Normal or ↑ | | **Schistocytes** | Present | Present | Absent | Absent | | **Bleeding + Thrombosis** | Yes | Yes | Thrombosis only | Thrombosis only | | **Underlying cause** | Malignancy | APL (t15;17) | Heparin exposure | Antiphospholipid Ab | ### Why This Is Cancer-Associated DIC (Not APL-DIC) **Clinical Pearl:** While both APL and pancreatic cancer can cause DIC, the **clinical context is paramount**: - **APL-DIC:** Young patient (median age 40), acute leukemia presentation, Auer rods, t(15;17) on cytogenetics, response to ATRA/arsenic - **Cancer-DIC:** Older patient (52 years), known solid malignancy (pancreatic cancer), no hematologic malignancy features This patient has **pancreatic cancer**, which is the **#1 solid tumor cause of DIC** (incidence 5–10% at diagnosis, up to 30% at autopsy). Pancreatic cancer cells express tissue factor constitutively, driving continuous thrombin generation. **Mnemonic:** **MALT** — Malignancies causing DIC: - **M**yeloid leukemia (APL) - **A**denocarcinoma (lung, pancreas, stomach, colon) - **L**ymphoma - **T**rophy (metastatic disease) ### Key Distinguishing Features 1. **Schistocytes present:** Excludes HIT (no mechanical hemolysis in HIT) and APS (no MAHA) 2. **Prolonged PT/aPTT + low fibrinogen:** Excludes HIT (coagulation normal in HIT) and APS (coagulation typically normal) 3. **Markedly elevated D-dimer:** Hallmark of DIC; normal in HIT and APS 4. **Pancreatic cancer as trigger:** Pancreatic adenocarcinoma is the **highest-risk malignancy** for DIC **High-Yield:** Pancreatic cancer has the **highest incidence of DIC among solid tumors** (5–10% at diagnosis). Lung, gastric, and colorectal cancers are also high-risk. ### Management Priorities 1. **Treat the underlying malignancy** — chemotherapy, surgery, or targeted therapy 2. **Supportive care:** Fresh frozen plasma (FFP) for coagulation factor replacement, cryoprecipitate for fibrinogen, platelet transfusion as needed 3. **Anticoagulation:** Controversial; low-dose heparin (5,000 U SC q6h) may be considered in some cases to interrupt the coagulation cascade, but bleeding risk is high 4. **Monitor:** Serial PT, aPTT, fibrinogen, D-dimer, platelet count every 6–12 hours **Warning:** Do NOT give heparin empirically in DIC without careful risk–benefit analysis; bleeding often dominates the clinical picture.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.